CTRI/2010/091/000160已完成3 期
A randomized double blind, placebo-controlled clinical trial to assess the effects of taspoglutide (RO5073031) on cardiovascular outcomes in subjects with inadequately controlled type 2 diabetes and established cardiovascular disease
F HoffmannLa Roche Ltd0 个研究点目标入组 2,000 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 2,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion Criteria:
- •adult patients, more than 18 years of age
- •diabetes mellitus type 2
- •HbA1c more than or equal to 6.5% and less than or equal to 10% at screening
- •BMI more than or equal to 23kg/m2
- •cardiovascular disease with onset more than or equal to month prior to screening
排除标准
- •Exclusion Criteria:
- •diagnosis or history of type 1 diabetes or secondary forms of diabetes
- •acute metabolic diabetic complications within past 6 months
- •severe hypoglycemia </=1 month prior to screening
- •clinically significant gastrointestinal disease
- •history of chronic or acute pancreatitis
- •current NYHA class IV heart failure or post-transplantation cardiomyopathy
- •severely impaired renal function
研究者
相似试验
进行中（未招募）
不适用
A randomized double blind, placebo-controlled clinical trial to assess the effects of taspoglutide (RO5073031) on cardiovascular outcomes in subjects with inadequately controlled type 2 diabetes and established cardiovascular disease - EMERGE 8EUCTR2009-014986-22-CZF. Hoffmann-La Roche Ltd2,000
进行中（未招募）
不适用
A randomized double blind, placebo-controlled clinical trial to assess the effects of taspoglutide (RO5073031) on cardiovascular outcomes in subjects with inadequately controlled type 2 diabetes and established cardiovascular disease - EMERGE 8EUCTR2009-014986-22-LTF. Hoffmann-La Roche Ltd2,000
进行中（未招募）
不适用
A randomized double blind, placebo-controlled clinical trial to assess the effects of taspoglutide (RO5073031) on cardiovascular outcomes in patients with inadequately controlled type 2 diabetes and established cardiovascular disease - EMERGE 8Patients with Type 2 diabetesMedDRA version: 12.0Level: LLTClassification code 10067585Term: Type 2 diabetes mellitusEUCTR2009-014986-22-GBF. Hoffmann-La Roche Ltd2,000
进行中（未招募）
不适用
A randomized double blind, placebo-controlled clinical trial to assess the effects of taspoglutide (RO5073031) on cardiovascular outcomes in subjects with inadequately controlled type 2 diabetes and established cardiovascular disease - EMERGE 8Patients with Type 2 diabetesMedDRA version: 12.0Level: LLTClassification code 10067585Term: Type 2 diabetes mellitusEUCTR2009-014986-22-HUF. Hoffmann-La Roche Ltd2,000
进行中（未招募）
不适用
A randomized double blind, placebo-controlled clinical trial to assess the effects of taspoglutide (RO5073031) on cardiovascular outcomes in subjects with inadequately controlled type 2 diabetes and established cardiovascular disease - EMERGE 8Patients with Type 2 diabetesMedDRA version: 12.0Level: LLTClassification code 10067585Term: Type 2 diabetes mellitusEUCTR2009-014986-22-DKF. Hoffmann-La Roche Ltd2,000